Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11261254 Antibodies

Patent 11261254 was granted and assigned to Genmab A/S on March, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
Genmab A/S
Date Filed
October 5, 2021
Date of Patent
March 1, 2022
Patent Applicant
‌
Genmab A/S
Patent Application Number
17494545
Patent Citations
‌
US Patent 10590206 Inert format
‌
US Patent 10906991 Bispecific antibodies and methods for production thereof
0
‌
US Patent 10597464 Heterodimeric antibody Fc-containing proteins and methods for production thereof
‌
US Patent 10150813 Anti-B7-H4 antibodies and immunoconjugates
‌
US Patent 10344050 Production of heterodimeric proteins
0
‌
US Patent 10407501 Humanized or chimeric CD3 antibodies
0
‌
US Patent 10465006 Humanized or chimeric CD3 antibodies
‌
US Patent 10544220 Bispecific antibodies against CD3 and CD20
Patent Inventor Names
Sieto Bosgra
0
Louise Koopman
0
Patrick Engelberts
0
Rik Rademaker
0
David Satijn
0
Dennis Verzijl
0
Edward N. Van Den Brink
0
Esther C. W. Breij
0
Frederikke L. Egerod
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11261254
Patent Primary Examiner
‌
Meera Natarajan

Find more entities like US Patent 11261254 Antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.